Clinical ophthalmology (Auckland, N.Z.) · 2026
Safety and Efficacy of the Ahmed ClearPath versus Ahmed ClearPath Small Tube at Six Months: A Retrospective Comparative Cohort Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shi Kelvin S Y, Dorairaj Emily Aashna, Bhartiya Shibal, Oyama Kody, Wang Weiwei, Thé Ryan Y, Moreno Kevin Bryce, Wang Melanie, Towne Caleb, Qozat Ibrahim M, Banoub Raphael G, Dorairaj Syril K
Аннотация
PURPOSE: To compare the safety and efficacy of the Ahmed ClearPath® (ACP) and Ahmed ClearPath® Small Tube (ACP-ST) in the management of glaucoma.
METHODS: This retrospective comparative study included 15 ACP eyes and 15 ACP-ST eyes. Outcomes compared through 6 months included intraoperative pressure (IOP), medication burden, surgical success, BCVA, and complications. Complete surgical success was definied as a ≥ 20% reduction in IOP from baseline with postoperative IOP > 5 mmHg and no additional glaucoma surgery or medication.
RESULTS: Baseline IOP and medication were similar between cohorts. At 6 months, mean IOP decreased from 28.13 ± 7.68 to 10.73 ± 3.63 mmHg in the ACP cohort (p < 0.0001) and from 27.15 ± 6.72 to 12.00 ± 5.32 mmHg in the ACP-ST cohort (p = 0.0001), with no significant difference between groups (p = 0.4535). Mean medication use decreased from 2.93 ± 0.80 to 0.73 ± 1.03 in the ACP cohort (p = 0.0005) and from 3.47 ± 1.46 to 1.00 ± 1.00 in the ACP-ST cohort (p < 0.0001), with no significant difference between groups (p = 0.4785). No intraoperative complications, postoperative hypotony, or IOP spikes occurred in either cohort.
CONCLUSIONS: Preliminary findings suggest that the ACP-ST may achieve IOP and medication reductions comparable to the ACP through 6 months. No postoperative hypotony was observed in the ACP-ST cohort despite the absence of tube ligation. However, given the sample size and differences in surgical technique, larger prospective controlled studies are needed to determine whether the smaller lumen independently contributes to flow control.
METHODS: This retrospective comparative study included 15 ACP eyes and 15 ACP-ST eyes. Outcomes compared through 6 months included intraoperative pressure (IOP), medication burden, surgical success, BCVA, and complications. Complete surgical success was definied as a ≥ 20% reduction in IOP from baseline with postoperative IOP > 5 mmHg and no additional glaucoma surgery or medication.
RESULTS: Baseline IOP and medication were similar between cohorts. At 6 months, mean IOP decreased from 28.13 ± 7.68 to 10.73 ± 3.63 mmHg in the ACP cohort (p < 0.0001) and from 27.15 ± 6.72 to 12.00 ± 5.32 mmHg in the ACP-ST cohort (p = 0.0001), with no significant difference between groups (p = 0.4535). Mean medication use decreased from 2.93 ± 0.80 to 0.73 ± 1.03 in the ACP cohort (p = 0.0005) and from 3.47 ± 1.46 to 1.00 ± 1.00 in the ACP-ST cohort (p < 0.0001), with no significant difference between groups (p = 0.4785). No intraoperative complications, postoperative hypotony, or IOP spikes occurred in either cohort.
CONCLUSIONS: Preliminary findings suggest that the ACP-ST may achieve IOP and medication reductions comparable to the ACP through 6 months. No postoperative hypotony was observed in the ACP-ST cohort despite the absence of tube ligation. However, given the sample size and differences in surgical technique, larger prospective controlled studies are needed to determine whether the smaller lumen independently contributes to flow control.